Market closed
Nurix Therapeutics/$NRIX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Ticker
$NRIX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
286
Website
NRIX Metrics
BasicAdvanced
$1.3B
-
-$2.88
2.14
-
Price and volume
Market cap
$1.3B
Beta
2.14
52-week high
$27.37
52-week low
$9.91
Average daily volume
683K
Financial strength
Current ratio
6.462
Quick ratio
6.375
Long term debt to equity
3.85
Total debt to equity
5.371
Management effectiveness
Return on assets (TTM)
-25.98%
Return on equity (TTM)
-53.22%
Valuation
Price to revenue (TTM)
20.758
Price to book
2.43
Price to tangible book (TTM)
2.43
Price to free cash flow (TTM)
-6.226
Growth
Revenue change (TTM)
-29.15%
Earnings per share change (TTM)
8.86%
3-year revenue growth (CAGR)
22.40%
3-year earnings per share growth (CAGR)
1.82%
What the Analysts think about NRIX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Nurix Therapeutics stock.
NRIX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
NRIX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
NRIX News
AllArticlesVideos
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
GlobeNewsWire·3 weeks ago
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Nurix Therapeutics stock?
Nurix Therapeutics (NRIX) has a market cap of $1.3B as of February 24, 2025.
What is the P/E ratio for Nurix Therapeutics stock?
The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of February 24, 2025.
Does Nurix Therapeutics stock pay dividends?
No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of February 24, 2025.
When is the next Nurix Therapeutics dividend payment date?
Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nurix Therapeutics?
Nurix Therapeutics (NRIX) has a beta rating of 2.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.